Nurse’s Notes: Drugs can help control Parkinson’s symptoms

2011-06-28T06:45:00Z 2012-03-27T08:03:49Z Nurse’s Notes: Drugs can help control Parkinson’s symptomsBy CHRIS FROELICH for the Missoulian

Parkinson’s disease is a progressive disease that occurs when certain cells in the brain that produce dopamine deteriorate. Dopamine is a chemical signal essential for nervous system control of muscle movement. The onset of symptoms – a slight tremor, loss of balance, rigid limbs, decreased facial expressions – happens gradually. Even after drug treatment becomes necessary, many patients have years before serious complications arise.

During early stages of Parkinson’s, the doctor might wait to prescribe drugs until symptoms begin to interfere with daily activities. Exercise, physical therapy and occupational therapy can be helpful at all stages of Parkinson’s disease. Simplifying daily activities to conserve energy for essential tasks is also recommended. There is no cure or treatment that slows the progression of Parkinson’s; however, there are drugs that are effective at controlling symptoms.

Medications used to treat Parkinson’s disease aim to correct the dopamine deficiency in the brain. For most patients, the drug of first choice is levodopa/carbidopa (Sinemet, Parcopa and various generic products). It passes into the brain and is converted into dopamine. As the disease progresses, the benefit from levodopa/carbidopa therapy can wax and wane, requiring medication adjustments or additions. Common side effects of levodopa/carbidopa products include involuntary movements (dyskinesias), nausea, confusion or hallucinations.

Dopamine agonists, another class of Parkinson’s drugs, boost the effects of dopamine. They might be the first agent used in people with mild symptoms. Pramipexole (Mirapex) and ropinirole (Requip) are the two most frequently used medications in this class. Longer duration of action per dose of medication and the ability to smooth the on and off effects of levodopa are two benefits associated with these medications. Possible side effects of dopamine agonists include hallucinations, sleepiness, water retention and low blood pressure when standing. These medications might also increase the risk of compulsive behaviors.

Monoamine oxidase type B (MAO-B) inhibitors and catechol O-methyltransferase (COMT) inhibitors help prevent the breakdown of dopamine and levodopa. Selegiline (Eldepryl) and rasagiline (Azilect) are the most common MAO-B inhibitors, and entacapone is the most common COMT inhibitor. Entacapone is available by itself (Comtan) or combined with carbidopa and levodopa in a medication called Stevelo. Adjustment in levodopa/carbidopa doses might be required if entacapone is added to minimize side effects. The side effects of MAO-B inhibitors are rare but can include confusion, headache,

hallucinations, and dizziness. The MAO-B inhibitors shouldn’t be used with many herbal supplements and other drugs, especially some antidepressants.

A class of drugs known as anticholinergics, which includes benztropine (Cogentin) and amantadine (Symmetrel), has been used to help control the tremor associated with Parkinson’s disease. A number of these drugs are available; however, their modest benefits are often offset by side effects such as impaired memory, confusion, constipation, dry mouth and eyes, and impaired urination.

Nearly 5 million people globally have Parkinson’s disease. The underlying cause remains elusive and the available drugs do not cure the disease, but with careful management they may help to control symptoms, prolong independence and maintain the highest possible quality of life. Combination of two or more drug classes often becomes necessary as the disease progresses from mild to more severe forms. Drug regimens are highly individualized and should be monitored and managed by an experienced doctor.

Chris Froelich is a Doctor of Pharmacy candidate on rotation at St. Patrick Hospital.

Copyright 2015 All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

No Comments Posted.

Missoulian Civil Dialogue Policy

Civil Dialogue Policy for Commenting on

We provide this community forum for readers to exchange ideas and opinions on the news of the day. Passionate views, pointed criticism and critical thinking are welcome. Comments can only be submitted by registered users. By posting comments on our site, you are agreeing to the following terms:

Commentary and photos submitted to the Missoulian ( may be published or distributed in print, electronically or other forms. Opinions expressed in's comments reflect the opinions of the author, and are not necessarily the opinions of the Missoulian or its parent company. See the Terms of Service and Privacy Policy for more information.

Our guidelines prohibit the solicitation of products or services, the impersonation of another site user, threatening or harassing postings and the use of vulgar, abusive, obscene or sexually oriented language, defamatory or illegal material. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual orientation, disability or other classification. It's fine to criticize ideas, but ad hominem attacks on other site users are prohibited. Users who violate those standards may lose their privileges on

You may not post copyrighted material from another publication. (Link to it instead, using a headline or very brief excerpt.)

No short policy such as this can spell out all possible instances of material or behavior that we might deem to be a violation of our publishing standards, and we reserve the right to remove any material posted to the site.

Add Comment
You must Login to comment.

Click here to get an account it's free and quick